Fast Five Quiz: Precision Medicine in Cancer

Winston W. Tan, MD; Evelyn S. Marienberg, MD


January 06, 2023

The evolution of the treatment landscape for NSCLC marks a shift in precision medicine. Historically, platinum-based doublets were chosen for every patient. Now during diagnosis, all patients with metastatic NSCLC should undergo molecular testing measuring EGFR, ALK, ROS1, PD-L1, NRTK, BRAF, MET, ERBB2 (HER2), RET, and KRAS to help determine whether a targeted therapy or immunotherapy should be used, per the National Comprehensive Cancer Network (NCCN).

Although pathways of oncogenic addiction have been characterized the most in lung cancer, researchers have also made strides in providing personalized medicine in the areas of colorectal cancer, breast cancer, leukemia, lymphoma, melanoma, esophageal cancer, stomach cancer, ovarian cancer, pancreatic cancer, and thyroid cancer.

Learn more about genetic testing to select targeted therapies for patients with NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.